Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy response of rivoglitazone HCl on the
change in HbA1c after 12 weeks of treatment in patients with type 2 diabetes.